Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10932)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22242)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5651)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (642)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22265)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors
    Meeting Abstract

    Raufi, A. G.; Goyal, L.; Smyth, E.; Szekeres, P.; Petrone, M.; Hobson, R.; Thress, K.; Origuchi, M.; Nehra, J.; Brown, J. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease-positive pancreatic and colorectal cancer
    Meeting Abstract

    Devoe, C. E.; Pant, S.; Wainberg, Z. A.; Chung, V.; George, T. J.; Kasi, P. M.; VanWyk, H.; Tavares, A.; Perry, J.; Kheoh, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205)
    Meeting Abstract

    Lim, K. H.; Spencer, K. R.; Safyan, R. A.; Picozzi, V. J.; Varghese, A. M.; Siolas, D.; Perez, K.; Clift, S.; Denis, L. J.; Bhambhani, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Meeting Abstract

    Segal, N. H.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Kinnaman, M. D.; Han, H.; Skokos, D.; Casey, K. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HLA associations with immunotherapy related endocrine toxicity
    Meeting Abstract

    Quandt, Z.; Thorball, C.; Middha, P.; Johnson, D. B.; Bejan, C. A.; Yao, L.; Xu, Y.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial
    Meeting Abstract

    Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L. G.; Hook, E. S.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; Paik, P. K.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry
    Meeting Abstract

    Luo, J.; Kim, J. J.; Walton, S. A.; Nguyen, T.; Paik, P. K.; Chaft, J. E.; Hsu, R.; Piha-Paul, S. A.; Janne, P. A.; Sholl, L. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
    Meeting Abstract

    Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer
    Meeting Abstract

    Chen, R. C.; Mazza, G. L.; Fruth, B.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma
    Meeting Abstract

    Kelley, R. K.; Cleary, J. M.; Sahai, V.; Baretti, M.; Bridgewater, J. A.; Hua, Z.; Gliser, C.; Bian, Y.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save